Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Molecular Pathway Controls Metastasis in Mouse Melanoma Model

By LabMedica International staff writers
Posted on 05 Jan 2015
Cancer researchers have found that the protein Chi3l1 (Chitinase 3-like-1) stimulates formation of metastases in a mouse model under the regulatory influence of the protein semaphorin 7a (Sema7a) and its receptors.

The CHI3L1 gene encodes a glycoprotein member of the glycosyl hydrolase 18 family. More...
The protein product lacks chitinase activity and is secreted by activated macrophages, chondrocytes, neutrophils, and synovial cells. The protein is thought to play a role in the process of inflammation and tissue remodeling. Semaphorins are a class of secreted and membrane proteins that act as axonal growth cone guidance molecules. They primarily act as short-range inhibitory signals and signal through multimeric receptor complexes with plexins being the major class of semaphorin receptor proteins.

Chi3l1 was found in earlier studies to be induced in cancers where it indicated a poor prognosis. However, it has not been known whether it actually contributed to cancer progression. To address this gap in knowledge investigators at Brown University (Providence, RI, USA) examined the production of Chi3l1 in a mouse model of melanoma lung metastases.

They reported in the December 15, 2014, online edition of the journal Cancer Research that Chi3l1 levels were elevated in mice, as in humans, with progressing cancer. Chi3l1 was induced during pulmonary melanoma metastasis, and this induction was regulated by Sema7a, interacting in stimulatory or inhibitory ways with its beta-1 integrin or Plexin C1 receptors, respectively. In mouse strains with genetic deletions of CHI3L1 or Sema7a, there was a significant reduction in pulmonary metastasis. Furthermore, antiserum raised against Chi3l1 or Sema7a induced the same reduction in metastasis as was produced by genetic deletions. Melanoma lung metastasis was also decreased in the absence of the cytokine IL-13Ralpha2, a recently identified receptor for Chi3l1, consistent with a key role for Chi3l1 in melanoma spread.

"We think everybody has Chitinase 3-like-1 (Chi3l1) in them because it plays a major role in our ability to fight off infections," said senior author Dr. Jack A. Elias, professor of medicine and biological sciences at Brown University. "But one of the things this paper shows is that inducing this molecule seems to be very important in the ability of tumors to spread. That leads us to believe this may be a fundamental pathway in the generation of metastases. We know what molecules are involved in the triggering of this. We do not know where they are and which of them are on the tumor and which are in the normal tissue around the tumor."

Related Links:

Brown University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.